Dexmedetomidine on Prevention of Side Effects of Hemabate

Jin Ni

Status and phase: Unknown; Phase 4

Conditions: Gynecological Patient

Treatments: Drug: high dose dexmedetomidine; Drug: low dose dexmedetomidine; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02220361

JNi

DAGZWCMC (Other Identifier)

Details and patient eligibility

About

Hemabate is often used for gynecological patients. Hemabate is associated with many side effects, including a burning sensation in the stomach, nausea, vomiting, diarrhea etc. It is reported that dexmedetomidine reduce gastrointestinal reaction during perioperative period. We design this clinical trial to find if dexmedetomidine can prevent the side effects of hemabate in Cesarean Section patients.

Enrollment: 120 patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

gynecological patients

Exclusion criteria

• Neuromuscular and endocrine diseases
• Allergic reactions to a2-adrenergic agonist
• Previous abdominal surgery including prior caesarean section.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

120 participants in 3 patient groups, including a placebo group

placebo group

Placebo Comparator group

Description:

received 20 ml intravenous physiological saline

Treatment:

Drug: placebo

low dose dexmedetomidine group

Experimental group

Description:

received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline

Treatment:

Drug: low dose dexmedetomidine

hemabate+high dose dexmedetomidine group

Experimental group

Description:

received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline

Treatment:

Drug: high dose dexmedetomidine